Antitumor T Cell Responses in Patients With Bladder Cancer

Study of Antitumor T Cell Immune Responses in Patients With Bladder Cancer

The main objective of this study is to evaluate the induction of Th1 anti-TERT responses by treatments in patients with bladder tumor.

Inclusion Criteria:

• Patients undergoing transurethral resection of the bladder (TURBT) for a tumor detected by cystoscopy with a histological diagnosis of a non-infiltrating or muscle-infiltrating tumor
• For muscle-invasive tumors: localized tumors (T2-T3N0M0) or locally advanced (T4N0M0)
• Written informed consent

Exclusion Criteria:

• History of TURBT for a bladder tumor whatever the stage
• Stages N1-3 or M1 on initial assessment
• Patients under immunotherapy, chemotherapy or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed)
• History of cancer in the last 3 years other than basal cell carcinoma or non-invasive cervical cancer
• HIV, hepatitis C or B infection
• Patients with any medical or psychiatric condition or disease,
• Patients under guardianship, curatorship or under the protection of justice.